News coverage about AstraZeneca (NYSE:AZN) has trended positive on Sunday, according to Accern Sentiment. The research group ranks the sentiment of news coverage by reviewing more than 20 million blog and news sources in real-time. Accern ranks coverage of companies on a scale of negative one to positive one, with scores nearest to one being the most favorable. AstraZeneca earned a media sentiment score of 0.25 on Accern’s scale. Accern also gave press coverage about the company an impact score of 45.6261067899242 out of 100, indicating that recent news coverage is somewhat unlikely to have an impact on the company’s share price in the next several days.
Here are some of the news headlines that may have effected Accern’s analysis:
- Leerink Swann Comments on AstraZeneca plc’s FY2019 Earnings (AZN) (americanbankingnews.com)
- Head to Head Review: Veru (VERU) vs. AstraZeneca (AZN) (americanbankingnews.com)
- Leerink Swann Comments on AstraZeneca plc’s Q1 2018 Earnings (AZN) (americanbankingnews.com)
- AstraZeneca (AZN) Price Target Raised to $38.00 at Leerink Swann (americanbankingnews.com)
- BNP Paribas says it posted a 'solid' 2017 despite profit slump in last quarter (finance.yahoo.com)
Shares of AstraZeneca (NYSE AZN) traded down $0.49 during midday trading on Friday, reaching $33.61. 8,800,000 shares of the company traded hands, compared to its average volume of 4,510,000. The stock has a market cap of $83,560.00, a price-to-earnings ratio of 28.48, a PEG ratio of 2.03 and a beta of 0.74. The company has a debt-to-equity ratio of 0.93, a quick ratio of 0.72 and a current ratio of 0.80. AstraZeneca has a 12 month low of $28.43 and a 12 month high of $36.70.
AstraZeneca (NYSE:AZN) last announced its earnings results on Friday, February 2nd. The company reported $1.30 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.44 by $0.86. AstraZeneca had a net margin of 13.36% and a return on equity of 34.74%. The company had revenue of $5.78 billion for the quarter, compared to analysts’ expectations of $5.49 billion. During the same quarter in the previous year, the company posted $1.21 EPS. The firm’s quarterly revenue was up 3.4% on a year-over-year basis. research analysts predict that AstraZeneca will post 1.67 EPS for the current fiscal year.
The firm also recently announced a semiannual dividend, which will be paid on Monday, March 19th. Shareholders of record on Friday, February 16th will be paid a dividend of $0.95 per share. The ex-dividend date of this dividend is Thursday, February 15th. This represents a yield of 5.62%. AstraZeneca’s dividend payout ratio (DPR) is presently 116.10%.
AZN has been the subject of a number of recent analyst reports. BMO Capital Markets set a $38.00 target price on shares of AstraZeneca and gave the stock a “buy” rating in a research note on Wednesday, November 15th. Citigroup upgraded shares of AstraZeneca to a “buy” rating in a research note on Wednesday, October 18th. Zacks Investment Research raised shares of AstraZeneca from a “sell” rating to a “hold” rating in a research report on Wednesday, January 10th. Cowen reissued a “hold” rating and set a $37.00 price target on shares of AstraZeneca in a research report on Tuesday, October 17th. Finally, Leerink Swann reissued a “market perform” rating and set a $36.00 price target (up from $33.00) on shares of AstraZeneca in a research report on Thursday, January 18th. Three analysts have rated the stock with a sell rating, eight have assigned a hold rating, thirteen have given a buy rating and one has assigned a strong buy rating to the company’s stock. The stock presently has an average rating of “Hold” and an average price target of $35.20.
AstraZeneca Company Profile
AstraZeneca PLC (AstraZeneca) is a biopharmaceutical company. The Company focuses on discovery and development of products, which are then manufactured, marketed and sold. The Company focuses on three main therapy areas: Oncology, Cardiovascular & Metabolic Disease (CVMD) and Respiratory, while selectively pursuing therapies in Autoimmunity, Infection and Neuroscience.
Receive News & Ratings for AstraZeneca Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AstraZeneca and related companies with MarketBeat.com's FREE daily email newsletter.